Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISP-001 in Mucopolysaccharidosis Type I Hurler-Scheie and Scheie
NCT05682144Phase 1Recruiting
- Sponsor
- Immusoft
- Start
- Apr 2023
- Primary completion
- Jun 2029
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of genleukocel-t in mucopolysaccharidosis type I (2 arms), sponsored by Immusoft. Primary endpoint: Number of participants with treatment-related adverse events and serious adverse events at 24 weeks. Started Apr 2023; status: recruiting.
02
Drugs
genleukocel-t
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT05682144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05682144.